CryptoSlate
A small biotech company is asking shareholders to approve a 951% increase in authorised shares, with the proceeds earmarked for buying an illiquid crypto token rather than funding its own drug pipeline. The proposal lands as the Bitcoin treasury trade that powered Strategy, Metaplanet and a wave of European entrants shows its first cracks: Strategy's BTC Yield is sliding, Metaplanet trades below the value of its coins, and dilution-heavy raises are no longer being rewarded by the market.
Why it matters
For two years, the playbook was simple: a public company issues shares or convertible debt, buys Bitcoin, and the stock re-rates higher on a multiple of net asset value. That reflex is breaking. MNAV premiums have compressed across the sector, and shareholders are starting to price dilution as a cost rather than as a free option. A biotech pivoting cash earmarked for clinical work into a thinly traded token is the kind of proposal that tests where the floor now sits.
Market impact
The pattern matters beyond any single name. Every treasury-company raise from here will be read against Strategy's sliding BTC Yield and Metaplanet's sub-NAV mark. Issuers that ask for outsized dilution into illiquid assets will likely see the market price it as a red flag rather than a growth bet, accelerating the crackdown already underway on the looser end of the crypto-treasury trade.
Frequently asked questions
-
What is the biotech asking shareholders to approve?
A 951% increase in authorised shares, with proceeds earmarked for buying an illiquid crypto token rather than funding its own drug pipeline.
-
Why is the Bitcoin treasury trade considered to be cracking?
Strategy's BTC Yield is sliding, Metaplanet now trades below the value of its coins, and dilution-heavy raises are no longer being rewarded by the market.
-
What is MNAV and why does its compression matter?
MNAV is the multiple of net asset value at which a treasury company trades versus its crypto holdings. Compressed premiums mean shareholders are pricing dilution as a cost rather than rewarding it as a free option.
-
How have treasury companies historically funded Bitcoin purchases?
Public companies have typically issued shares or convertible debt, bought Bitcoin, and watched the stock re-rate higher on a multiple of net asset value, a reflex that is now breaking.
-
What signal does this biotech proposal send to the wider market?
It tests how far shareholders will stretch on dilution into illiquid assets, and likely accelerates the crackdown already underway on the looser end of the crypto-treasury trade.
CoinDesk
Crypto Rank News
TheBlock
Crypto Capital Venture
CoinTelegraph
Whale Alert
Lookonchain
Glassnode